Tenaya net loss widens to $43.39 million in Q2 FY26; R&D expenses slip to $16.6 million
Reuters2026/08/05 20:44- Tenaya Therapeutics posted a Q2 net loss of USD 43.4 million, or USD 0.20 a share, widening from USD 23.3 million, or USD 0.14, a year earlier.
- R&D expense edged down to USD 16.6 million from USD 17.4 million; G&A expense fell to USD 5.4 million from USD 6.7 million.
- Collaboration revenue was USD 1.11 million; the net loss widened mainly due to a USD 21.8 million non-cash impairment tied to early lease termination.
- Cash and cash equivalents totaled USD 78.1 million as of June 30; a USD 10 million Alnylam upfront payment helped extend runway through Q3 2027.
- Interim data for TN-201 and TN-401 showed improvements in key disease measures; additional data and pivotal-trial regulatory updates are expected in Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
10-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
